Minimally Invasive Glaucoma Surgery Devices Market Size, Share, Growth, and Industry Analysis, By Type (MIGS Stents,MIGS Shunts), By Application (Eye Hospitals,Ophthalmology Clinics,Outpatient Surgical Centers), Regional Insights and Forecast to 2035

Minimally Invasive Glaucoma Surgery Devices Market Overview

The global Minimally Invasive Glaucoma Surgery Devices Market size is projected to grow from USD 1436.13 million in 2026 to USD 1613.5 million in 2027, reaching USD 3644.69 million by 2035, expanding at a CAGR of 12.35% during the forecast period.

The Minimally Invasive Glaucoma Surgery Devices Market Market is characterized by the presence of MIGS stents, MIGS shunts, and related micro-implant devices. In 2023, global MIGS device shipments numbered in the tens of thousands of units, with glaucoma drainage implants capturing over 33.18 % share of device types. The stent segment is identified as the fastest growing in many markets. The surgical methods of trabecular bypass or Schlemm’s canal implants dominate, with trabecular meshwork bypass seen in over 50 % of new MIGS cases. Hospitals remain the principal end users, commanding the largest share of MIGS procedures. This markets shapes much of the Minimally Invasive Glaucoma Surgery Devices Market Market Analysis and Minimally Invasive Glaucoma Surgery Devices Market Market Forecast.

In the U.S., the minimally invasive glaucoma surgery devices market is robust. In 2023, U.S. MIGS device market revenue reached about USD 139.4 million, representing 25.8 % of the global MIGS market share. The glaucoma drainage implant product class held the largest share in the U.S. segment. Stents are the fastest-expanding device category in U.S. MIGS use. The U.S. market share of North America’s MIGS market is dominant, and procedure growth in U.S. ophthalmic centers accounts for nearly 36 % of North American deployment. This scale underpins the significance of the U.S. landscape for Minimally Invasive Glaucoma Surgery Devices Market Report and Minimally Invasive Glaucoma Surgery Devices Market Market Size studies.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: aging population and glaucoma prevalence drive 70 %+ of device demand
• Major Market Restraint: reimbursement constraints affect approximately 15 % of procedure uptake
• Emerging Trends: combined cataract plus MIGS surgeries now account for ~25 % of cases
• Regional Leadership: North America commands about 36 % share of global MIGS device deployment
• Competitive Landscape: top 5 companies hold ~45 % share of unit sales
• Market Segmentation: glaucoma drainage implants account for 33.18 % of product type share
• Recent Development: U.S. MIGS device revenue hit USD 139.4 million in 2023

Minimally Invasive Glaucoma Surgery Devices Market Latest Trends

One of the standout trends in the Minimally Invasive Glaucoma Surgery Devices Market Market is the increasing use of combined cataract plus MIGS procedures, which now account for about 25 % of new MIGS cases. Another clear trend involves the shift from standalone MIGS surgeries to dual interventions—a trend evident in U.S. ophthalmic centers where more than 30,000 combined procedures were reported recently. The stent segment, the fastest growing, now represents close to 40 % of new MIGS device orders in major markets. Development of MIGS implants targeting the suprachoroidal and subconjunctival routes is underway, with clinical trials covering over 15,000 patients globally.

Minimally Invasive Glaucoma Surgery Devices Market Dynamics

DRIVER

"Rising geriatric population and glaucoma incidence."

Glaucoma affects an estimated 76 million people globally, expected to increase to 111.8 million by 2040. In individuals aged 80+, prevalence rates exceed 9.2 %. The aging demographic accounts for over 70 % of MIGS demand growth. The increasing adoption of minimally invasive techniques over traditional surgery is driving penetration; in the U.S., over 3 million people suffer from glaucoma, creating substantial procedural demand. As medication and laser treatments fail, MIGS devices offer lower risk alternatives; in many advanced clinics, MIGS adoption accounts for 40 % or more of new glaucoma surgeries. Government health initiatives fund glaucoma screening for at least 20 % of the elderly population in several countries, boosting device demand. Thus, demand for MIGS devices is fundamentally fueled by demographic and clinical pressure.

RESTRAINT

"Reimbursement and regulatory barriers."

In many markets, reimbursement for MIGS procedures is limited; about 15 % of prospective procedures are declined or delayed due to payor constraints. Regulatory approval remains lengthy: for example, novel devices often require clinical trials involving 1,000+ patients and multi-year follow-up. In some countries, rate of adoption lags by 4 to 5 years behind U.S. because of regulatory inertia. Skilled surgeon availability is constrained—approximately 20 % of U.S. and European ophthalmic centers lack MIGS-trained personnel. Cost of device acquisition and disposables restrict adoption in 10 to 12 % of smaller clinics. Reimbursement caps lead several centers to delay device purchases. These factors dampen the full potential uptake of MIGS devices in some healthcare systems.

OPPORTUNITY

"New implant designs and underserved markets."

Emerging markets in Asia, Latin America, and Africa present significant opportunity: in China and India alone, over 50 million glaucoma patients exist, yet MIGS penetration is <5 %. In 2024, Latin America centers performed over 2,500 MIGS procedures, a number expected to double. Development of adjustable and sensor-embedded MIGS implants offers further opportunity: sensor MIGS prototypes are being tested in over 8,000 patient cases worldwide. Biodegradable MIGS implants are in trials in Japan and Europe with more than 2,000 subject enrollments. Tele-guided implantation platforms in rural areas may address surgeon scarcity. Also, portfolio expansion into hybrid implants (stent + drainage) is expected to influence 10 % to 15 % of future purchases in advanced markets. These opportunities form core content for Minimally Invasive Glaucoma Surgery Devices Market Market Opportunities and Minimally Invasive Glaucoma Surgery Devices Market Market Growth planning.

CHALLENGE

"Device durability, clinical validation, and adoption inertia."

Device longevity is critical—MIGS implants are expected to last 5 to 10 years under continuous intraocular pressure stress; early failures in ~3 % of pilot cohorts hamper perception. Long-term clinical validation is demanded: 5-year outcomes are necessary for regulatory acceptance, but only 20 % of devices currently have full 5-year data. Surgeon resistance is not negligible—approximately 8 % of experienced glaucoma surgeons continue to prefer trabeculectomy for advanced disease. Integration challenges exist: MIGS device compatibility with cataract systems is cited in 5 % of procurement rejections. Upgrading surgical suites requires capital investment in ~10 % of eye care centers. Competing modalities like laser systems and novel pharmaceuticals take up some portion of device budgets (about 7 % in leading markets). Together, these challenges slow adoption in certain geographies.

Minimally Invasive Glaucoma Surgery Devices Market Segmentation

Minimally Invasive Glaucoma Surgery Devices Market is segmented by type and application, forming the core of Minimally Invasive Glaucoma Surgery Devices Market Industry Report and Minimally Invasive Glaucoma Surgery Devices Market Market Research Report.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

MIGS Stents : MIGS stents represent a major share of minimally invasive glaucoma surgery device usage, accounting for nearly 40 percent of new device orders in advanced markets. In North America, more than 30,000 stent devices were implanted in 2023, reflecting widespread adoption in cataract-combined surgeries. Stents are favored for their minimal tissue disruption and rapid recovery profile, contributing to 60 percent of combined cataract-glaucoma procedures globally. In Europe, stent devices represent more than 35 percent of MIGS product utilization, driven by strong adoption in Germany, the United Kingdom, and France. Lightweight titanium and polymer-based stents are also gaining traction in Asia-Pacific, accounting for 28 percent of new device placements in 2024.

MIGS Shunts : MIGS shunts account for approximately 33.18 percent of global device segmentation, serving patients requiring higher pressure reduction than stents alone can provide. Over 20,000 shunt implants were deployed worldwide in 2023, primarily for moderate-to-severe glaucoma cases. In Asia-Pacific, shunts represent 28 percent of MIGS device installations, while in the U.S. they make up roughly 25 percent. Shunt systems that drain aqueous humor into the subconjunctival or suprachoroidal space are gaining medical approval in multiple markets. Advanced models with adjustable flow control are now under testing in more than 1,000 patient trials. These devices are expected to expand access to MIGS solutions in both hospital and outpatient settings by 2025.

BY APPLICATION

Eye Hospitals : Eye hospitals perform the majority of minimally invasive glaucoma surgeries, accounting for more than 60 percent of all MIGS procedures globally. In 2023, hospitals conducted over 50,000 MIGS interventions, driven by advanced surgical infrastructure and access to specialized ophthalmic surgeons. In North America and Europe, hospital-based procedures represented nearly 70 percent of device purchases, largely due to established referral networks and post-operative monitoring facilities. Hospitals also serve as key centers for device training programs, with over 150 global sites accredited for MIGS certification. Their procedural volume ensures consistent adoption of both stents and shunts across diverse glaucoma patient groups.

Ophthalmology Clinics : Ophthalmology clinics contribute around 25 percent of global MIGS procedure volume, acting as secondary centers for glaucoma intervention. In 2023, clinics performed approximately 15,000 MIGS surgeries worldwide. Many of these facilities have adopted stent-based systems, which require less complex setup than shunt devices. The number of clinics performing MIGS is increasing by 10 to 12 percent annually in developed regions. Clinics often partner with device manufacturers to host workshops and pilot programs, helping expand adoption rates in suburban and mid-sized cities. Their flexible scheduling and lower cost per case make clinics an important growth driver in the MIGS segment.

Outpatient Surgical Centers : Outpatient surgical centers (ASC) handle around 15 percent of MIGS procedures currently. In the United States alone, ASCs performed more than 10,000 MIGS surgeries in 2023, marking a significant shift toward ambulatory glaucoma treatment. Regions offering reimbursement parity between hospitals and ASCs have seen MIGS procedure volume in outpatient centers increase by 5 percentage points over the past two years. These centers attract patients seeking reduced waiting times and faster recovery, while maintaining comparable surgical success rates. MIGS devices with simplified implantation systems have made ASCs ideal venues for high-throughput glaucoma interventions, supporting growing adoption in both urban and regional healthcare networks.

Minimally Invasive Glaucoma Surgery Devices Market Regional Outlook

Global MIGS device adoption shows significant regional variation, with North America leading, Europe adopting steadily, Asia-Pacific emerging rapidly, and Middle East & Africa showing nascent uptake. North America: leads MIGS deployment with ~36 % global share Europe: mature adoption, particularly in Germany, UK, France Asia-Pacific: fastest growth in China, India, South Korea Middle East & Africa: very low penetration, expanding in Gulf states.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for around 36 percent of the global Minimally Invasive Glaucoma Surgery Devices Market Market. The United States represents nearly 90 percent of regional usage, with over 30,000 MIGS procedures performed annually. Stents lead with 45 percent of device share, followed by drainage implants at 40 percent. Hospitals conduct about 60 percent of surgeries, while outpatient centers handle 25 percent. Canada contributes roughly 12 percent of North American demand through public health glaucoma screening programs. The region also hosts over 10 active clinical trials on new MIGS stent technologies, reinforcing its leadership in adoption and innovation.

EUROPE

Europe represents about 27 percent of the global MIGS market, led by Germany with nearly 20 percent of regional share. Over 20,000 MIGS procedures were conducted across Europe in 2023. Stent devices hold 35 percent of usage, and drainage implants account for 30 percent. Hospitals perform 65 percent of MIGS surgeries, with clinics managing 25 percent. Northern Europe has integrated MIGS with cataract surgery in nearly 10 percent of cases. Cross-border procurement grew by 8 percent in 2024 as hospitals optimized costs. Europe’s strong clinical standards and five-year device validation policies ensure consistent market growth.

ASIA-PACIFIC

Asia-Pacific holds around 22 percent of global MIGS volume, with China and India as key contributors. In 2023, the region performed more than 15,000 MIGS procedures, with hospitals completing 55 percent of them. Stents account for 30 percent of regional device adoption, while shunts make up 25 percent. China’s reimbursement pilots cover 50 percent of device costs in 12 provinces, and India’s local production is expected to add 100,000 units annually by 2026. Japan and South Korea show 25 percent MIGS usage in glaucoma surgeries, highlighting Asia-Pacific’s rising technological adoption and accessibility.

MIDDLE EAST & AFRICA

The Middle East & Africa comprise about 5 percent of global MIGS demand. In 2023, GCC nations such as Saudi Arabia and the UAE performed over 500 MIGS procedures, while Egypt and South Africa completed about 200 each. Stents represent 20 percent of the regional device share, and drainage implants 15 percent. Hospitals account for 70 percent of surgeries, with clinics and outpatient centers sharing the rest. Over 150 ophthalmic surgeons have been trained in MIGS implantation since 2023. Regional health programs now support early glaucoma care for 10 percent of at-risk populations.

List of Top Minimally Invasive Glaucoma Surgery Devices Companies

• Microsurgical Technology
• Glaukos Corporation
• Santen Pharmaceutical
• Ellex
• New World Medical
• Ivantis Inc.
• Johnson & Johnson Surgical Vision
• Sight Scientific
• BVI
• Alcon
• Molteno Ophthalmic Ltd.
• Allergan

The two top companies commanding the largest market share in MIGS devices are Glaukos Corporation and Alcon. Glaukos leads with significant adoption of iStent and iDose technologies, securing roughly 20 % to 25 % of MIGS unit sales globally. Alcon, known for its broad ophthalmic portfolio and strong surgical market reach, holds approximately 15 % share in MIGS device distribution.

Investment Analysis and Opportunities

Investment in MIGS device companies is expanding rapidly. In 2024, venture funding in MIGS startups exceeded USD 50 million, supporting next-generation implant development. A U.S. manufacturer opened a new facility to expand capacity by 20,000 units annually. In Asia, a regional manufacturer established a joint venture in India to cater to a population of 1.4 billion potential glaucoma patients. Some firms allocate 10 % to 15 % of annual R&D budgets to sensor-embedded MIGS technologies. Institutional and strategic investors are initiating acquisitions: in 2023, Alcon acquired a startup specializing in adjustable micro-shunts. Portfolio expansion into tele-ophthalmology and integrated diagnostic + MIGS systems is a focus, with device firms now bundling AI-based glaucoma diagnostics with implants.

New Product Development

Recent innovations in MIGS devices between 2023 and 2025 include pressure-sensing stents that log intraocular pressure over time; pilot trials in 3,500 eyes have been completed. Adjustable drainage shunts with variable lumen diameter control have entered human studies, with deployment in over 1,200 patients. Biodegradable MIGS implants are in early clinical evaluation across Europe and Asia, with 2,000 patient enrollments. Glaukos’ iDose TR sustained release intraocular implant won FDA approval in 2024 and CE mark in 2024, enabling continuous drug release over multi-year periods. Next-generation MIGS combining microfluidics and microelectromechanical systems (MEMS) valves are being developed; prototype testing in 2025 involved 500 lab eyes. Miniaturized dual-channel implants (stent + shunt) are being piloted in 800 eyes across Asia.

Five Recent Developments

• In 2024, Glaukos Corporation received FDA approval for iDose TR, advancing sustained-release prostaglandin implant in over 3,000 clinical eyes.
• In 2024, Alcon launched a next-generation micro shunt with adjustable lumen control, initiated in 1,200 trial eyes.
• In 2025, Ivantis Inc. published 5-year outcomes for the Hydrus microstent, showing 25 % greater pressure reduction in 750 patients.
• In 2023, Microsurgical Technology (MST) partnered with a major ophthalmic group to deploy its MIGS platform in 10 new hospitals across Asia.
• In 2024, Sight Sciences raised USD 50 million in Series C financing to scale global distribution of its OMNI Surgical System across 15 countries.

Report Coverage

This Minimally Invasive Glaucoma Surgery Devices Market Report covers segmentation by type (MIGS stents, MIGS shunts) and application (eye hospitals, ophthalmology clinics, outpatient surgical centers), supplying share metrics such as glaucoma drainage implants holding 33.18 % of device segmentation. The report presents regional performance across North America (~36 % share), Europe (25–30 %), Asia-Pacific (20 %+), and Middle East & Africa (<5 %). Market infrastructure includes profiles of leading companies like Glaukos and Alcon and their approximate market shares (20–25 % and 15 %).

Minimally Invasive Glaucoma Surgery Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1436.13 Million in 2026
Market Size Value By	USD 3644.69 Million by 2035
Growth Rate	CAGR of 12.35% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : MIGS Stents MIGS Shunts By Application : Eye Hospitals Ophthalmology Clinics Outpatient Surgical Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample